Moderna COVID-19 Vaccine

Kathryn Dzintars, Pharm.D., BCPS
Moderna COVID-19 Vaccine is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

VACCINE TYPE

  • The Moderna COVID-19 vaccine (mRNA-1273) is a lipid nanoparticle-encapsulated, nucleoside-modified messenger RNA vaccine that encodes the SARS-CoV-2 spike glycoprotein.
    • Two-dose series, given one month (28 days) apart
    • A third dose can be administered to select immunocompromised patients a minimum of 28 days after the initial 2-dose series (see below).
    • A booster dose is recommended for most individuals 18 years or older beginning 6 months after completion of the initial 2-dose series.
  • The U.S. FDA issued an Emergency Use Authorization (EUA) to permit the emergency use of the Moderna COVID-19 vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older.
    • Mandatory requirements for the administration of mRNA-1273 under the EUA are as follows:
      • The vaccine is authorized in patients ≥ 18 years of age.
      • The vaccination provider must give the individual receiving the Moderna COVID-19 vaccine or their caregiver the “Fact Sheet for Recipients and Caregivers” prior to the individual receiving the Moderna COVID-19 vaccine.
      • Vaccine providers must include vaccine information to either the state’s or local jurisdiction’s Immunization Information System or other designated systems.
      • Vaccine providers are responsible for reporting certain events to the Vaccine Adverse Events Reporting System (VAERS):
        • Vaccine administration errors whether or not associated with an adverse event
        • Serious adverse events include death, life-threatening adverse events, inpatient hospitalization/prolonged hospitalization, persistent or significant incapacity, congenital anomaly/birth defects
        • Cases of a multisystem inflammatory syndrome (MIS) in children and adults
        • Cases of COVID-19 that result in hospitalization and death
      • Vaccine providers are responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Moderna or Pfizer-BioNTech COVID-19 Vaccine to recipients.
  • There are no data on the interchangeability of COVID-19 vaccines. If the primary series is initiated with the Moderna product, the primary should be completed with the Moderna product.
    • Booster doses can be provided with any of the COVID-19 vaccines that are approved for use in the U.S. (Janssen, Moderna, Pfizer)
  • On August 12, 2021, the EUA was modified to include the administration of a third dose after the initial 2-dose primary series to certain immunocompromised patients (solid organ transplant, active treatment of solid or hematologic malignancies, CAR-T or prolonged immunosuppressive therapy, advanced/untreated HIV infection, active treatment with prednisone ≥20 mg/day)
    • The additional dose should be the same vaccine product as the original two-dose series.
    • Administer the additional dose at least 28 days after the completion of the initial two-dose series (this is based on expert opinion only).
  • On October 21, 2021, the CDC recommended booster vaccines for most individuals.
    • The following are eligible for a booster:
      • Anyone aged 65 years or older
      • ≥ 18 years of age and living in long-term care facilities, nursing homes, etc
      • ≥ 18 years of age and have underlying health conditions (e.g. cancer, CKD, chronic lung disease)
      • ≥ 18 years of age and work or live in high-risk settings (e.g. first responders, educators, public transit workers
    • Booster doses can be provided with any of the COVID-19 vaccines that are approved for use in the U.S. (Janssen, Moderna, Pfizer)
    • Booster doses should be administered beginning 6 months after the initial 2-dose primary series

-- To view the remaining sections of this topic, please or --

VACCINE TYPE

  • The Moderna COVID-19 vaccine (mRNA-1273) is a lipid nanoparticle-encapsulated, nucleoside-modified messenger RNA vaccine that encodes the SARS-CoV-2 spike glycoprotein.
    • Two-dose series, given one month (28 days) apart
    • A third dose can be administered to select immunocompromised patients a minimum of 28 days after the initial 2-dose series (see below).
    • A booster dose is recommended for most individuals 18 years or older beginning 6 months after completion of the initial 2-dose series.
  • The U.S. FDA issued an Emergency Use Authorization (EUA) to permit the emergency use of the Moderna COVID-19 vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older.
    • Mandatory requirements for the administration of mRNA-1273 under the EUA are as follows:
      • The vaccine is authorized in patients ≥ 18 years of age.
      • The vaccination provider must give the individual receiving the Moderna COVID-19 vaccine or their caregiver the “Fact Sheet for Recipients and Caregivers” prior to the individual receiving the Moderna COVID-19 vaccine.
      • Vaccine providers must include vaccine information to either the state’s or local jurisdiction’s Immunization Information System or other designated systems.
      • Vaccine providers are responsible for reporting certain events to the Vaccine Adverse Events Reporting System (VAERS):
        • Vaccine administration errors whether or not associated with an adverse event
        • Serious adverse events include death, life-threatening adverse events, inpatient hospitalization/prolonged hospitalization, persistent or significant incapacity, congenital anomaly/birth defects
        • Cases of a multisystem inflammatory syndrome (MIS) in children and adults
        • Cases of COVID-19 that result in hospitalization and death
      • Vaccine providers are responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Moderna or Pfizer-BioNTech COVID-19 Vaccine to recipients.
  • There are no data on the interchangeability of COVID-19 vaccines. If the primary series is initiated with the Moderna product, the primary should be completed with the Moderna product.
    • Booster doses can be provided with any of the COVID-19 vaccines that are approved for use in the U.S. (Janssen, Moderna, Pfizer)
  • On August 12, 2021, the EUA was modified to include the administration of a third dose after the initial 2-dose primary series to certain immunocompromised patients (solid organ transplant, active treatment of solid or hematologic malignancies, CAR-T or prolonged immunosuppressive therapy, advanced/untreated HIV infection, active treatment with prednisone ≥20 mg/day)
    • The additional dose should be the same vaccine product as the original two-dose series.
    • Administer the additional dose at least 28 days after the completion of the initial two-dose series (this is based on expert opinion only).
  • On October 21, 2021, the CDC recommended booster vaccines for most individuals.
    • The following are eligible for a booster:
      • Anyone aged 65 years or older
      • ≥ 18 years of age and living in long-term care facilities, nursing homes, etc
      • ≥ 18 years of age and have underlying health conditions (e.g. cancer, CKD, chronic lung disease)
      • ≥ 18 years of age and work or live in high-risk settings (e.g. first responders, educators, public transit workers
    • Booster doses can be provided with any of the COVID-19 vaccines that are approved for use in the U.S. (Janssen, Moderna, Pfizer)
    • Booster doses should be administered beginning 6 months after the initial 2-dose primary series

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: November 18, 2021